Zetomipzomib (KZR-616) Treatment Results in Clinically Meaningful Renal Responses in Patients with Lupus Nephritis (EULAR 2023) - Apr 2, 2023 - Abstract #POS1128; Pres time: Jun 2, 2023; 09:30 AM - 10:30 AM; Location: Poster View; P1b/2 | "*Complete Renal Response: UPCR ≤0.5, eGFR ≥60 mL/min/1.73m 2 or no worsening of eGFR from baseline of ≥25%, prednisone (or equivalent) ≤10 mg and no use of prohibited medication. Conclusion In the MISSION Phase 2 study, treatment with zetomipzomib 60 mg SC QW for 24 weeks demonstrated strong activity against LN as evidenced by improvement in UPCR and has the potential to be a long-term, steroid-sparing immunomodulatory treatment for LN patients."
Clinical • Glomerulonephritis • Immune Modulation • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • CD163
|
|
A. Saxena 1; S. Parikh2; S. Hua3; R. Leff4; E. Park5; N. Henig6
|